Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fuji
Healthtrust
Fish and Richardson
AstraZeneca
Federal Trade Commission
Teva
Citi
Covington

Generated: May 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,846,695

« Back to Dashboard

Summary for Patent: 8,846,695
Title:Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy.
Inventor(s): Dugi; Klaus (Dresden, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:13/143,370
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,846,695
Patent Claims: 1. A method for treating type 2 diabetes mellitus in a patient with inadequate glycemic control despite therapy with metformin, said method comprising orally administering 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine to said patient in an amount of 5 mg per day in combination with metformin.

2. A method for treating type 2 diabetes mellitus in a patient with inadequate glycemic control despite therapy with metformin, said method comprising orally administering 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine to said patient in an amount of 5 mg per day as add-on combination with metformin.

3. The method according to claim 1, wherein said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1- yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is administered in an amount of 5 mg once daily to said patient.

4. The method according to claim 1, wherein said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine is administered in an amount of 2.5 mg twice daily to said patient.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
QuintilesIMS
AstraZeneca
Express Scripts
Chinese Patent Office
Mallinckrodt
US Department of Justice
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.